H.C. Wainwright analyst Yi Chen downgraded Alimera Sciences (ALIM) to Neutral from Buy with an unchanged price target of $6 after the company entered into a definitive agreement under which ANI Pharmaceuticals (ANI) would acquire Alimera for $5.50 per share in cash plus a non-tradable contingent value right of up to 50c per share upon the achievement of certain net revenue targets in 2026 and 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)
- Alimera Sciences Reports First Quarter 2024 Results
- ALIM Earnings Report this Week: Is It a Buy, Ahead of Earnings?